RESUMEN
BACKGROUND: Despite a strong link between Helicobacter Pylori infection and peptic ulcer disease (PUD), rates of testing for H. Pylori in hospitalized patients with PUD remain largely unexplored. We aimed to determine H. Pylori testing practices at our institution among inpatients with PUD, and to implement a protocol to improve testing rates. MATERIALS AND METHODS: In this quality improvement initiative, baseline H. Pylori testing practices were determined by analysis of historical data on 100 subsequent inpatients with PUD from January 2016 to June 2017 at a tertiary care hospital undergoing esophagogastroduodenoscopy (EGD). Subsequently, a division-wide testing protocol was implemented, and data were analyzed from 43 consecutive inpatients with PUD from October 2019-March 2020 to determine the protocol's effects. RESULTS: The analysis of baseline testing practices showed a 57% testing rate for H. Pylori. Gastric biopsies were less likely to be performed during EGDs done outside the endoscopy unit (5.9% vs 32.7%, P = 0.001), outside of usual business hours (6.7% vs 24.3%, P = 0.04), and in cases where endoscopic therapy was administered (6% vs 32%, P = 0.02). After implementation of the new division-wide testing protocol, testing rates increased to 93% (P < 0.001). CONCLUSIONS: Low baseline inpatient testing for H. Pylori represents a missed opportunity to test a substantial number of high-risk patients with PUD. Implementation of a conceptually simple protocol aimed at increasing rates of gastric biopsy significantly improved testing rates in a prospective follow-up. Widespread standardization of H. Pylori testing for inpatients with PUD may improve important patient outcomes related to complicated PUD.
Asunto(s)
Infecciones por Helicobacter , Úlcera Péptica , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/aislamiento & purificación , Humanos , Pacientes Internos , Úlcera Péptica/diagnóstico , Úlcera Péptica/microbiología , Estudios Prospectivos , Mejoramiento de la CalidadRESUMEN
BACKGROUND AND AIMS: Benign gastrointestinal (GI) strictures are often refractory to standard endoscopic interventions. Fully covered coaxial lumen-apposing metal stents (LAMS) have emerged as a novel therapy for these strictures. The aim of this study was to evaluate the safety and efficacy of LAMS for refractory GI strictures. PATIENTS AND METHODS: A retrospective analysis was performed for patients who underwent LAMS placement for benign luminal strictures in three US centers between January 2014 and December 2016.âThe primary outcomes were technical success and initial clinical success of LAMS placement. Secondary outcomes were stent migration, rate of re-intervention, and adverse events. RESULTS: A total of 49 patients underwent 56 LAMS placement procedures. Previous treatment had failed in 39 patients (79.6â%), and anastomotic strictures were the indication in 77.6â% (38/49), with the most common site being gastrojejunal (34.7â% [17/49]). Technical success was achieved in all procedures and initial clinical success was achieved in 96.4â% of all procedures (54/56). Patient initial clinical success was 95.9â% (47/49). Stent migration occurred in 17.9â% of procedures, and was more likely to occur at sites in the lower GI tract ( P â=â0.02). The mean stent dwell time was 100.6 days, and the mean follow-up was 169.8 days. Minor adverse events, not requiring hospitalization, occurred in 33.9â% of procedures, including subsequent stricture progression (10.7â%). In cases where LAMS were removed, mean follow-up time was 102.2 days. The re-intervention rate was 75â% at 300 days follow-up after stent removal. Of the LAMS placed at anastomotic strictures, 36.4â% required re-intervention, with approximately two-thirds of these re-interventions requiring placement of a new stent or surgery. CONCLUSION: LAMS placement was successful for the management of refractory GI strictures, with good technical and initial clinical success rates. However, re-intervention rates after LAMS removal were high, and many strictures were not resolved by an extended period of stenting with these coaxial stents. LAMS placement offers additional therapeutic options and in selected cases might be considered a destination therapy for patients with recalcitrant benign strictures.